ATE286501T1 - Pyrimidinderivate - Google Patents

Pyrimidinderivate

Info

Publication number: ATE286501T1
Authority: AT; Austria
Prior art keywords: halogeno; pyrimidine derivatives; trifluoromethyl; cyano; hydroxy
Prior art date: 1999-10-13

Application number

AT00968084T

Other languages

English (en)

Inventor

John Graham Cumming

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-13

Filing date

2000-10-10

Publication date

2005-01-15

2000-10-10 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-01-15 Application granted granted Critical

2005-01-15 Publication of ATE286501T1 publication Critical patent/ATE286501T1/de

Links

229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
125000005843 halogen group Chemical group 0.000 abstract 3
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)

AT00968084T 1999-10-13 2000-10-10 Pyrimidinderivate ATE286501T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9924092.1A GB9924092D0 (en)	1999-10-13	1999-10-13	Pyrimidine derivatives
PCT/GB2000/003929 WO2001027089A1 (en)	1999-10-13	2000-10-10	Pyrimidine derivatives

Publications (1)

Publication Number	Publication Date
ATE286501T1 true ATE286501T1 (de)	2005-01-15

Family

ID=10862569

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00968084T ATE286501T1 (de)	1999-10-13	2000-10-10	Pyrimidinderivate

Country Status (18)

Country	Link
US (1)	US6846827B1 (de)
EP (1)	EP1226126B1 (de)
JP (1)	JP2003511442A (de)
KR (1)	KR100738862B1 (de)
CN (1)	CN100415724C (de)
AT (1)	ATE286501T1 (de)
AU (1)	AU772293B2 (de)
BR (1)	BR0014596A (de)
CA (1)	CA2382605A1 (de)
DE (1)	DE60017279T2 (de)
GB (1)	GB9924092D0 (de)
HK (1)	HK1045511B (de)
IL (2)	IL148428A0 (de)
MX (1)	MXPA02003533A (de)
NO (1)	NO322808B1 (de)
NZ (1)	NZ517572A (de)
WO (1)	WO2001027089A1 (de)
ZA (1)	ZA200201557B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9816837D0 (en)	1998-08-04	1998-09-30	Zeneca Ltd	Amide derivatives
US7772432B2 (en)	1991-09-19	2010-08-10	Astrazeneca Ab	Amidobenzamide derivatives which are useful as cytokine inhibitors
DK1017378T3 (da)	1997-09-23	2003-03-17	Astrazeneca Ab	Amidderivater til behandling af sygdomme medieret af cytokiner
IL139710A (en)	1998-05-15	2005-07-25	Astazeneca Ab	Benzamide derivatives for the treatment of diseases mediated by cytokines
BR9912729A (pt)	1998-08-04	2001-05-02	Astrazeneca Ab	Derivado de amida, processo para prepará-lo, e, uso do mesmo
ATE254105T1 (de)	1998-09-25	2003-11-15	Astrazeneca Ab	Benzamid-derivate und ihre verwendung als cytokine inhibitoren
EP1163212B1 (de)	1999-03-17	2005-08-31	AstraZeneca AB	Amid-derivate
DE60010448T2 (de)	1999-03-17	2005-04-07	Astrazeneca Ab	Amid-derivate
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
CA2396693A1 (en) *	1999-12-28	2001-07-05	Stephen T. Wrobleski	Cytokine, especially tnf-alpha, inhibitors
US6943161B2 (en)	1999-12-28	2005-09-13	Pharmacopela Drug Discovery, Inc.	Pyrimidine and triazine kinase inhibitors
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6670357B2 (en)	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US7122544B2 (en)	2000-12-06	2006-10-17	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en)	2000-12-06	2006-10-31	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6716851B2 (en)	2000-12-12	2004-04-06	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
AU2002316421B2 (en)	2001-06-26	2008-05-15	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-ALPHA expression
GB0124939D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0202873D0 (en)	2002-02-07	2002-03-27	Novartis Ag	Organic compounds
MXPA04007737A (es) *	2002-02-11	2004-10-15	Pfizer	Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4.
CN100369898C (zh)	2002-02-12	2008-02-20	史密丝克莱恩比彻姆公司	用作p38抑制剂的烟酰胺衍生物
NZ535349A (en)	2002-03-08	2007-01-26	Signal Pharm Inc	JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
US7388009B2 (en)	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
PL219736B1 (pl)	2002-04-23	2015-07-31	Bristol Myers Squibb Co	Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie
ATE418546T1 (de)	2002-04-23	2009-01-15	Bristol Myers Squibb Co	Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
AU2003245989A1 (en)	2002-07-09	2004-01-23	Boehringer Ingelheim Pharma Gmbh And Co. Kg	Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
GB0308186D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308185D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308201D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
MXPA05013075A (es)	2003-06-03	2006-03-17	Novartis Ag	Inhibidores de p-38 basados en heterociclo de 5 miembros.
AU2004246800B2 (en) *	2003-06-13	2008-12-04	Novartis Ag	2-aminopyrimidine derivatives as Raf kinase inhibitors
CN1832928B (zh)	2003-06-26	2012-07-04	诺瓦提斯公司	以5元杂环为基础的p38激酶抑制剂
ATE412642T1 (de)	2003-07-25	2008-11-15	Novartis Ag	Inhibitoren von p-38-kinase
GB0318814D0 (en)	2003-08-11	2003-09-10	Smithkline Beecham Corp	Novel compounds
US7419978B2 (en)	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0324790D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Amide derivatives
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
US7285545B2 (en)	2004-05-03	2007-10-23	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokine inhibitors
EP1867646A1 (de) *	2004-05-03	2007-12-19	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokin-Inhibitoren
ES2328601T3 (es)	2004-06-28	2009-11-16	Bayer Schering Pharma Ag	Pirimidinas 4,6-disustituidas y su uso como inhibidores de proteina cinasa.
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
TW200618803A (en)	2004-08-12	2006-06-16	Bristol Myers Squibb Co	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060178388A1 (en)	2005-02-04	2006-08-10	Wrobleski Stephen T	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US7473784B2 (en)	2005-08-01	2009-01-06	Bristol-Myers Squibb Company	Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
US7754717B2 (en) *	2005-08-15	2010-07-13	Amgen Inc.	Bis-aryl amide compounds and methods of use
WO2007053452A1 (en) *	2005-11-01	2007-05-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US9598669B2 (en)	2005-12-29	2017-03-21	Anthrogenesis Corporation	Composition for collecting placental stem cells and methods of using the composition
AU2007223342A1 (en)	2006-03-07	2007-09-13	Bristol-Myers Squibb Company	Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
AU2007257650A1 (en) *	2006-06-15	2007-12-21	Boehringer Ingelheim International Gmbh	2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
WO2008057775A2 (en)	2006-10-27	2008-05-15	Bristol-Myers Squibb Company	Heterocyclic amide compounds useful as kinase inhibitors
US7943617B2 (en)	2006-11-27	2011-05-17	Bristol-Myers Squibb Company	Heterobicyclic compounds useful as kinase inhibitors
EP1992344A1 (de)	2007-05-18	2008-11-19	Institut Curie	P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
JP5600063B2 (ja)	2007-10-19	2014-10-01	セルジーンアビロミクスリサーチ，インコーポレイテッド	ヘテロアリール化合物およびその使用
US20100015708A1 (en) *	2008-06-18	2010-01-21	Mdrna, Inc.	Ribonucleic acids with non-standard bases and uses thereof
EP2300466B1 (de)	2008-06-20	2014-08-06	Bristol-Myers Squibb Company	Imidazopyridin- und imidazopyrazinverbindungen als kinasehemmer
WO2009155389A1 (en)	2008-06-20	2009-12-23	Bristol-Myers Squibb Company	Triazolopyridine compounds useful as kinase inhibitors
WO2010120963A1 (en) *	2009-04-16	2010-10-21	Bristol-Myers Squibb Company	Tablet formulation for p38 inhibitor and method
JP2013505262A (ja) *	2009-09-17	2013-02-14	バンダービルトユニバーシティー	ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法
WO2012031057A1 (en)	2010-09-01	2012-03-08	Bristol-Myers Squibb Company	Bms- 582949 for the treatment of resistant rheumatic disease
US8883819B2 (en)	2011-09-01	2014-11-11	Irm Llc	Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
SG11201406584TA (en)	2012-04-24	2014-11-27	Vertex Pharma	Dna-pk inhibitors
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
RS62649B1 (sr)	2013-03-12	2021-12-31	Vertex Pharma	Inhibitori dnk-pk
KR102411227B1 (ko)	2013-10-17	2022-06-21	버텍스 파마슈티칼스 인코포레이티드	Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
WO2015077246A1 (en)	2013-11-19	2015-05-28	Vanderbilt University	Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5
US9533982B2 (en)	2014-03-20	2017-01-03	Vanderbilt University	Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en)	2014-10-03	2017-01-24	Vanderbilt University	Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
MX394860B (es)	2016-09-27	2025-03-24	Vertex Pharma	Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
EA202091897A1 (ru)	2018-02-08	2020-10-27	Энио Фарма	Неконденсированные производные тиофена и их применение
CA3133964A1 (en) *	2019-03-18	2020-09-24	The Council Of The Queensland Institute Of Medical Research	Cardiomyocyte proliferation
US20240034726A9 (en) *	2020-02-28	2024-02-01	Dana-Farber Cancer Institute, Inc.	Map kinase kinase (mkk7) inhibitors and uses thereof
CN116789642A (zh) *	2022-03-18	2023-09-22	华东师范大学	一类诱导肿瘤细胞发生methuosis死亡的三芳香杂环哌嗪类化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9816837D0 (en)	1998-08-04	1998-09-30	Zeneca Ltd	Amide derivatives
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
US6096748A (en) *	1996-03-13	2000-08-01	Smithkline Beecham Corporation	Pyrimidine compounds useful in treating cytokine mediated diseases
GB9623833D0 (en)	1996-11-16	1997-01-08	Zeneca Ltd	Chemical compound
EP0994860A1 (de)	1997-07-03	2000-04-26	Du Pont Pharmaceuticals Company	Aryl- und arylamino-substituierte heteroringen als corticotropin freisetzende hormon antagonisten
DK1017378T3 (da)	1997-09-23	2003-03-17	Astrazeneca Ab	Amidderivater til behandling af sygdomme medieret af cytokiner
NZ506679A (en) *	1998-03-27	2002-11-26	Janssen Pharmaceutica Nv	HIV inhibiting pyrimidine derivatives
IL139710A (en)	1998-05-15	2005-07-25	Astazeneca Ab	Benzamide derivatives for the treatment of diseases mediated by cytokines
US6579872B1 (en)	1998-05-15	2003-06-17	Astrazeneca Ab	Bezamide derivatives for the treatment of diseases mediated by cytokines
BR9912729A (pt)	1998-08-04	2001-05-02	Astrazeneca Ab	Derivado de amida, processo para prepará-lo, e, uso do mesmo
ES2221414T3 (es) *	1998-08-27	2004-12-16	Sumitomo Pharmaceuticals Company, Limited	Derivados de pirimidina.
AU5438299A (en)	1998-08-29	2000-03-21	Astrazeneca Ab	Pyrimidine compounds
ATE336484T1 (de)	1998-08-29	2006-09-15	Astrazeneca Ab	Pyrimidine verbindungen
ATE254105T1 (de)	1998-09-25	2003-11-15	Astrazeneca Ab	Benzamid-derivate und ihre verwendung als cytokine inhibitoren
CN1158266C (zh)	1998-10-01	2004-07-21	阿斯特拉曾尼卡有限公司	化合物
EP1163212B1 (de)	1999-03-17	2005-08-31	AstraZeneca AB	Amid-derivate
DE60010448T2 (de)	1999-03-17	2005-04-07	Astrazeneca Ab	Amid-derivate
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds

1999
- 1999-10-13 GB GBGB9924092.1A patent/GB9924092D0/en not_active Ceased
2000
- 2000-10-10 MX MXPA02003533A patent/MXPA02003533A/es active IP Right Grant
- 2000-10-10 AU AU78042/00A patent/AU772293B2/en not_active Ceased
- 2000-10-10 JP JP2001530109A patent/JP2003511442A/ja active Pending
- 2000-10-10 BR BR0014596-3A patent/BR0014596A/pt not_active Application Discontinuation
- 2000-10-10 KR KR1020027004779A patent/KR100738862B1/ko not_active Expired - Fee Related
- 2000-10-10 CA CA002382605A patent/CA2382605A1/en not_active Abandoned
- 2000-10-10 NZ NZ517572A patent/NZ517572A/en unknown
- 2000-10-10 DE DE60017279T patent/DE60017279T2/de not_active Expired - Fee Related
- 2000-10-10 CN CNB008141452A patent/CN100415724C/zh not_active Expired - Fee Related
- 2000-10-10 EP EP00968084A patent/EP1226126B1/de not_active Expired - Lifetime
- 2000-10-10 US US10/070,360 patent/US6846827B1/en not_active Expired - Fee Related
- 2000-10-10 HK HK02107003.8A patent/HK1045511B/en not_active IP Right Cessation
- 2000-10-10 IL IL14842800A patent/IL148428A0/xx active IP Right Grant
- 2000-10-10 AT AT00968084T patent/ATE286501T1/de not_active IP Right Cessation
- 2000-10-10 WO PCT/GB2000/003929 patent/WO2001027089A1/en not_active Ceased
2002
- 2002-02-25 ZA ZA200201557A patent/ZA200201557B/en unknown
- 2002-02-27 IL IL148428A patent/IL148428A/en not_active IP Right Cessation
- 2002-04-12 NO NO20021728A patent/NO322808B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
US6846827B1 (en)	2005-01-25
NO322808B1 (no)	2006-12-11
KR20020091830A (ko)	2002-12-06
EP1226126A1 (de)	2002-07-31
ZA200201557B (en)	2003-07-30
IL148428A0 (en)	2002-09-12
KR100738862B1 (ko)	2007-07-13
HK1045511B (en)	2005-06-03
CA2382605A1 (en)	2001-04-19
MXPA02003533A (es)	2002-08-20
NZ517572A (en)	2003-11-28
AU772293B2 (en)	2004-04-22
IL148428A (en)	2006-12-10
AU7804200A (en)	2001-04-23
GB9924092D0 (en)	1999-12-15
JP2003511442A (ja)	2003-03-25
HK1045511A1 (en)	2002-11-29
DE60017279D1 (en)	2005-02-10
NO20021728D0 (no)	2002-04-12
CN100415724C (zh)	2008-09-03
EP1226126B1 (de)	2005-01-05
CN1378537A (zh)	2002-11-06
WO2001027089A1 (en)	2001-04-19
BR0014596A (pt)	2002-06-11
NO20021728L (no)	2002-06-12
DE60017279T2 (de)	2005-12-08

Legal Events

Date	Code	Title	Description
2005-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
NO20021728D0 (no)	2002-04-12	Pyrimidin-derivater
RU2324684C2 (ru)	2008-05-20	Пиримидиновые производные
ES2191462T3 (es)	2003-09-01	Derivados de quinolina y quinazolina y su uso como inhibidores de enfermedades mediadas por citoquinas.
MY140729A (en)	2010-01-15	Amide derivatives
PL346854A1 (en)	2002-03-11	Benzamide derivatives and their use as cytokine inhibitors
AU2003225617A1 (en)	2003-09-16	Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2004026863A8 (en)	2005-04-21	Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
NZ505453A (en)	2002-11-26	Hypolipidemic benzothiazepine compounds
DE60315674D1 (de)	2007-09-27	Neue imidazopyridine und ihre verwendung
WO2004026306A3 (en)	2004-07-01	Pyrazole derivatives as transforming growth factor (tgf) inhibitors
NO20020042L (no)	2002-03-04	Kinazoline derivater
SE0302573D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DK0665834T3 (da)	2001-09-10	Quinolon- og acridinonderivater til behandling af urininkontinens
RU2002100058A (ru)	2003-06-27	Кристаллические производные 1-метилкарбапенема
SE0300908D0 (sv)	2003-03-31	Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
DE60001586D1 (de)	2003-04-10	Diphenyl-piperidin derivate
DE60035429D1 (de)	2007-08-16	Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
SE0302570D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MX2007006744A (es)	2007-07-09	Derivados de hidantoina utiles como inhibidores de metaloproteinasa.
MY139613A (en)	2009-10-30	Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
HUP0203161A2 (hu)	2002-12-28	Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EE05300B1 (et)	2010-06-15	Akrloldistamtsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
YU25202A (sh)	2004-12-31	Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
EP2266566A3 (de)	2011-01-12	Nicotinamid Derivate und ihrer Verwendung als Therapeutika